4-Antibody is a biopharmaceutical company with a fully-human antibody drug-discovery technology platform that generates a pipeline of antibody therapeutics.
This proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates.
4-Antibody’s Retrocyte Display technology generates high-quality therapeutic antibody drug candidates using a rapid, high-throughput, flow cytometry approach incorporating full-length immunoglobulin (IgG) format human antibody libraries expressed in mammalian B cells.
The company provides access to its technologies to pharmaceutical research and development (R&D) collaborators but is also generating its own pipeline of antibody drugs. The firm’s lead development product is an anti-cytomegalovirus antibody drug.
4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland, and Jena, Germany.
With many different antibody discovery technologies now available to corporate pharmaceutical firms, 4-Antibody has differentiated its technology offering by utilising a B-cell display approach that combines the fidelity of mammalian B cell expression with the efficiency of an in-vitro, high-throughput display process to rapidly discover molecules with favourable performance characteristics as development leads.
4-Antibody aims to reduce development risk as early as possible in the antibody discovery process by selecting molecules more likely to display ‘better behaviour’ as drug candidates.
Retrocyte Display is a high-throughput in-vitro discovery process utilising cellular expression libraries that encode full-length human antibodies in B-lineage cells and mimic nature’s own antibody generation process.
This approach has been designed to reject molecules with less desirable drug characteristics as early as possible in the discovery process, and deliver lead molecules for preclinical characterisation that can be viewed as development-ready early in discovery with a resulting enhanced likelihood of eventual biological and physiological success.
4-Antibody also applies its Retrocyte Display technology in an R&D collaboration with the Ludwig Institute for Cancer Research and the Memorial Sloan Kettering Cancer Center in New York to develop therapeutic antibodies directed to a series of molecular targets with key roles in the suppression of immune responses in cancer patients
Tel: +41 61 633 22 60
Fax: +41 61 633 22 61
Winzerlaer Strasse 2